RedHill Biopharma Ltd (RDHL)

[noretreat]

This is important:

RedHill perceives MAP as an ongoing medical treat to the gut that has to be eliminated. For this reason, RHB-104 is clinically designed as an inward therapeutic approach to CD rather than outward approach. Most FDA approved therapeutics, immunomodulators, 5-ASA, corticosteroids, anti-IL-23 blockers (ustekinumab and risankizumab) and anti-TNF agents (Remicade, Humira), for CD are known to treat the symptoms to slow progression. In contrast, RHB-104 has been specifically designed to eradicate the root cause of the disease to halt the ensuing associated symptoms. This is an important and significant differentiation from its peers.

Read this!!!

https://seekingalpha.com/article/4216893-redhill-biopharma-rhbminus-104-takes-guts-achieve-success?app=1